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Background: Short-chain enoyl-CoA hydratase (SCEH, encoded by ECHS1) catalyzes hydration of 2-trans-enoyl-CoAs to
3(S)-hydroxy-acyl-CoAs. SCEH has a broad substrate specificity and is believed to play an important role in mitochondrial
fatty acid oxidation and in the metabolism of branched-chain amino acids. Recently, the first patients with SCEH
deficiency have been reported revealing only a defect in valine catabolism. We investigated the role of SCEH in fatty
acid and branched-chain amino acid metabolism in four newly identified patients. In addition, because of the Leigh-like
presentation, we studied enzymes involved in bioenergetics.
Methods: Metabolite, enzymatic, protein and genetic analyses were performed in four patients, including two siblings.
Palmitate loading studies in fibroblasts were performed to study mitochondrial β-oxidation. In addition, enoyl-CoA
hydratase activity was measured with crotonyl-CoA, methacrylyl-CoA, tiglyl-CoA and 3-methylcrotonyl-CoA both in
fibroblasts and liver to further study the role of SCEH in different metabolic pathways. Analyses of pyruvate
dehydrogenase and respiratory chain complexes were performed in multiple tissues of two patients.
Results: All patients were either homozygous or compound heterozygous for mutations in the ECHS1 gene,
had markedly reduced SCEH enzymatic activity and protein level in fibroblasts. All patients presented with lactic
acidosis. The first two patients presented with vacuolating leukoencephalopathy and basal ganglia abnormalities.
The third patient showed a slow neurodegenerative condition with global brain atrophy and the fourth patient
showed Leigh-like lesions with a single episode of metabolic acidosis. Clinical picture and metabolite analysis were
not consistent with a mitochondrial fatty acid oxidation disorder, which was supported by the normal palmitate
loading test in fibroblasts. Patient fibroblasts displayed deficient hydratase activity with different substrates tested.
Pyruvate dehydrogenase activity was markedly reduced in particular in muscle from the most severely affected
patients, which was caused by reduced expression of E2 protein, whereas E2 mRNA was increased.
Conclusions: Despite its activity towards substrates from different metabolic pathways, SCEH appears to be only
crucial in valine metabolism, but not in isoleucine metabolism, and only of limited importance for mitochondrial
fatty acid oxidation. In severely affected patients SCEH deficiency can cause a secondary pyruvate dehydrogenase
deficiency contributing to the clinical presentation.
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Short-chain enoyl-CoA hydratase (SCEH, EC4.2.1.17)
also called crotonase, encoded by ECHS1 catalyzes the
hydration of 2-trans-enoyl-CoAs to 3(S)-hydroxy-acyl-
CoAs [1] (Fig. 1). SCEH is believed to be one of the key
enzymes of the mitochondrial β-oxidation machinery,
catalyzing the second step of mitochondrial β-oxidation of
short- and medium-chain fatty acyl-CoAs [2]. The first
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Fig. 1 Biochemical pathways. The SCEH enzyme encoded by the ECHS1 gene
of valine, isoleucine and leucine are depicted. On the right side the pathway of
chain aminotransferase; BCKD complex, branched-chain alpha-keto acid dehyd
3-hydroxyisobutyrate dehydrogenase; HMG-CoA lyase, 3-hydroxy-3-methylgluta
MGH, 3-methylglutaconyl-CoA hydratase; IBD, isobutyryl-CoA dehydrogenase; I
dehydrogenase; MCC, 3-methylcrotonyl-CoA carboxylase; MMSDH, methylmalon
dehydrogenase; SCAD, short-chain acyl-CoA dehydrogenase; SCEH, short-
dehydrogenaseshort-chain fatty acyl-CoAs is catalyzed by medium-chain
acyl-CoA dehydrogenase (MCAD, encoded by ACADM)
and short-chain acyl-CoA dehydrogenase (SCAD, encoded
by ACADS), respectively. After formation of 3-hydroxy-
acyl-CoAs by SCEH, the third and fourth steps are cata-
lyzed by the medium- and short-chain hydroxyacyl-CoA
dehydrogenase (M/SCHAD, encoded by HADH) and
medium-chain 3-ketoacyl-CoA thiolase (MCKAT, encoded























tion Fatty acid oxidation
?
?
is involved in different metabolic pathways. On the left side the pathways
medium/short-chain fatty acid oxidation is depicted. BCAT, branched-
rogenase complex; HIBCH, 3-hydroxyisobutyryl-CoA hydrolase; HIBADH,
ryl-CoA lyase; MHBD, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase;
VD, isovaleryl-CoA dehydrogenase; MCAD, medium-chain acyl-CoA
ate semialdehyde dehydrogenase; SBCAD, short branched-chain acyl-CoA
chain enoyl-CoA hydratase; SCHAD, short-chain 3-hydroxyacyl-CoA
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shows greatest activity towards crotonyl-CoA (C4:1-CoA)
[1]. Next to straight-chain acyl-CoAs, SCEH is also active
with branched-chain acyl-CoAs, in particular intermedi-
ates of the degradation of the branched-chain amino acids
valine, isoleucine and leucine (Fig. 1). Purified SCEH from
rat liver has been shown to hydrate methacrylyl-CoA
(valine metabolism), tiglyl-CoA (isoleucine metabolism)
and 3-methylcrotonyl-CoA (leucine metabolism) [3–5].
Recently the first three patients with SCEH deficiency
(MIM 602292) were described all presenting with Leigh dis-
ease [6, 7]. For two siblings it was shown that they excreted
S-(2-carboxypropyl) cysteine and S-(2-carboxypropyl) cys-
teamine, which are cysteine and cysteamine conjugates of
methacrylyl-CoA, in addition to a newly identified meta-
bolite 2-methyl-2,3-dihydroxybutyrate [6]. The same me-
tabolites have been identified in 3-hydroxyisobutyryl-CoA
hydrolase (HIBCH) deficiency. HIBCH is the enzyme
downstream from SCEH in the valine catabolic pathway.
Interestingly, HIBCH-deficient patients also present with
a Leigh-like syndrome [8]. For this reason, SCEH defi-
ciency was primarily published as a novel inborn error af-
fecting valine metabolism. However, as described above
SCEH is also proposed to be active in the metabolism of
isoleucine and is believed to play an important role in
β-oxidation of medium- and short-chain fatty acids. In
addition, decreased pyruvate dehydrogenase enzyme activ-
ity had been noted in fibroblasts of the first two patients
described in [6] and a combined respiratory chain defi-
ciency was found in muscle from the third patient [7],
which may explain some of the clinical and biochemical
features of the patients including the lactic acidosis.
In this report, we describe four newly identified SCEH
deficient patients, including two siblings, which extends
our knowledge of this novel disorder. We studied the
enzymatic abnormalities in SCEH deficiency in more de-
tail. We used cultured skin fibroblasts and liver of these
patients to evaluate the role of SCEH in different meta-
bolic pathways, and, given the Leigh-like presentation,
we analyzed enzymes involved in bioenergetics in mul-




The infant was the product of a normal pregnancy with a
normal prenatal karyotype 46,XX to non-consanguineous
Hispanic parents. She was born by Caesarian section for
breech presentation at term with birth weight 2.7 kg (per-
centile 5th–10th), height 48 cm (25th–50th percentile),
and head circumference 35.5 cm (50th–90th percentile).
Depressed respiration due to maternal morphine adminis-
tration was reversed with naloxone and a small pneumo-
thorax due to positive pressure ventilation resolved withinhours on oxygen therapy. Subsequently, the child became
apneic, bradycardic, and hypoxemic, and was found to
have progressive lactic acidosis (pH 7.16, lactate 15.8 to
18.8 mM) and hyperammonemia (172 to 218 μM). An
echocardiogram showed poor biventricular contractility
and suprasystemic pulmonary hypertension with right to
left shunting over the ductus arteriosus. She was treated
with glucose, bicarbonate, multiple pressor support, and
nitric oxide. The child was unresponsive, had mild hepato-
megaly 3 cm below the right costal margin. She had wors-
ening lactic acidosis (pH 6.8, BE −29, anion gap 46, lactate
23 mM) and hyperammonemia (418 μM). She developed
ventricular tachycardia and fibrillation and died at 24 h of
life. Plasma amino acid analysis showed a markedly ele-
vated alanine level of 2300 μM (normal 131–710 μM) with
normal glutamine 800 μM, citrulline 20 μM and lysine
500 μM. Urine organic acids analysis revealed large lactate
and pyruvate peaks, and a large peak of 2-methyl-2,3-
dihydroxybutyric acid. Total and free carnitine levels in
plasma were normal, and the acylcarnitine profile
showed mild elevations of C3, C4, and C5 acylcarni-
tines. Blood counts and liver transaminases were nor-
mal, but creatine kinase was 3427 IU/L (normal <150)
and prothrombin time was prolonged with INR 2.72
(normal N-1.0). Lactate was 26 mM (normal < 2 mM)
and pyruvate 1.58 mM (normal < 0.2 mM) with a lactate:-
pyruvate ratio of 16 (normal 12–20); 3-hydroxybutyrate was
1.78 mM (normal < 0.2 mM) and acetoacetate was 0.24 mM
(normal < 0.1 mM), with a 3-hydroxybutyrate:acetoacetate
ratio of 7 (normal < 4). Lymphocyte pyruvate carboxylase
enzyme activity was normal (27 pmol/(min.mg protein),
normal > 6).
A rapid autopsy was performed with samples obtained
for metabolic testing. Pathological examination of brain
tissue revealed extensive macrocystic and microcystic
degeneration of the white matter with massive periven-
tricular cysts up to 1.8 cm diameter. There was wide-
spread spongy myelinopathy most prominent in the
brain stem nuclei and in the white matter including the
cerebellar white matter. There were multifocal microcal-
cifications and mild Alzheimer type II metabolic gliosis.
The liver had mixed macro and microvesicular steatosis,
but no specific mitochondrial abnormalities were identi-
fied on electron microscopy. The lungs had mild muscu-
larization of intralobular arterioles.
Patient 2
This child, the sister of patient 1, was born after an un-
eventful pregnancy at 39 weeks via Caesarian section with
birth weight 2.76 kg (<10th percentile), length 47 cm
(percentile 10–50) and head circumference 33.5 cm (per-
centile 10–50). She had a brief apnea which resolved with
continuous positive airway pressure and was weaned to
room air. She was vigorous and reactive with good tone.
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creasing from 6.5 mM to 12.1 mM as glucose infusion
was increased from 5.5 to 8.3 mg/(kg.min). A brain MRI
showed bilateral periventricular cysts and acute to sub-
acute necrotizing encephalomalacia in the cerebral white
matter but with a normal corpus callosum (Fig. 2). Due to
the suspicion of pyruvate dehydrogenase deficiency, intra-
venous ketogenic diet with a ketogenic ratio of 4:1 was ini-
tiated. The next day, the child became unresponsive and
unstable, developed pulmonary hypertension with ductus
arteriosis shunting and hemodynamic instability with
hypoxic respiratory failure, and required high frequency
oscillatory ventilation, inotropic and pressor support,
and inhaled nitric oxide. Lactic acidosis remained stable
around 8 to 10 mM, ketones developed with plasma 3-
hydroxybutyrate increasing from 0.3 to a maximum of
1.5 mM, with serum triglycerides 225 mg/dL. The child
developed an additional large non-anion gap metabolic
acidosis of 10 to 12 mM requiring bicarbonate supple-
mentation. Liver size and function remained normal.
Urine organic acids analysis revealed a high lactate peak
with little ketones, and a large peak of 2-methyl-2,
3-dihydroxybutyrate. Plasma amino acids showed elevated
alanine 1381 μM (normal 131–710 μM) and proline
506 μM (normal 110–417 μM). Plasma acylcarnitine
profile showed mildly increased short, medium and long-
chain carnitine esters especially elevated C3 1.11 μM
(reference range 0–0.55 μM) and elevated C4 1.26 μM
(0–0.46 μM). Ketogenic diet was discontinued for failure
to achieve sufficient ketosis. Given the worsening clinical
status and poor prognosis, intensive care support was
withdrawn and the child died on the second day of life. A
rapid metabolic autopsy was performed in less than one
hour after her death. Pathological examination of theFig. 2 Brain MRI of patient 2. FLAIR images of the brain of patient 2
showing multiple periventricular cystic lesions in addition to
attenuated signal in the subcortical white matterbrain revealed macrocystic and microcystic white matter
degeneration with periventricular cysts, cerebral and cere-
bellar white matter gliosis. There was mild thinning of the
corpus callosum, and rare focal neuronal heterotopia and
dyslamination. There was some excess glycogen in muscle
and liver, with hepatic macrovesicular and microvesicular
steatosis. The mitochondria appeared normal on electron
microscopy. Sequencing of mitochondrial DNA and of
POLG1 in blood did not reveal a pathogenic mutation.
Genomic copy number variants were evaluated with a
negative targeted array comparative genomic hybridi-
zation (aCGH) for mitochondrial and metabolism genes
(mitomet array), which showed a copy number loss of un-
known significance [arr 7q36.3 (158431591–158612961) ×1].
Due to the significant decrease in pyruvate dehy-
drogenase enzyme activity, PDHA1, PDHB, DLAT and
PDHX genes and the genes for the pyruvate carrier
MPC1 and MPC2 were all sequenced but no mutations
were identified.
Patient 3
The patient was a 7 year-old girl, first child to non-
consanguineous parents of Iraqi-Turkish Jewish ancestry
on the paternal side and Iraqi-Libyan Jewish ancestry on
the maternal side. Following an uneventful pregnancy,
the child was born at term, birth weight of 2.80 kg and
head circumference of 32 cm. Low muscle tone and
failure to gain developmental milestones were noted
since early infancy. At 4 months of age microcephaly,
bilateral sensorineural hearing loss and bilateral optic
atrophy were noted. The patient was fed via gastrostomy
because of swallowing difficulty. Recurrent apnea with
desaturation necessitated placement of a tracheostomy
and mechanical ventilation. Brain MRI revealed mild
ventricular dilatation at 2 months but on repeated exam-
ination at the age of 12 months, there was generalized
atrophy of the grey matter, thinning of the corpus callo-
sum, and symmetrical atrophy of the cerebellum and
brain stem. Transient non-obstructive hypertrophy of
the inter-ventricular septum was reported at 18 months
but resolved on repeated examination at age 3 years. At
age 7 years, weight was at the 95th percentile, length
10th percentile, and head circumference below the third
percentile. The palms and face were edematous, and the
eyes were wandering. There were no voluntary move-
ments, but there was withdrawal in response to pain.
She had low tone and contractures of the large joints.
Elevated levels of blood lactate 3.9–7.2 mM (nor-
mal <2.2 mM) and of alanine 700 μM (normal <547 μM)
were repeatedly noted. Urinary organic acids analysis
revealed increased excretion of lactate, Krebs cycle
metabolites, 2-methyl-2,3-dihydroxybutyrate and 3-
methylglutaconic acid. Urine metabolite screening by
tandem mass spectrometry showed increased levels of
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teamine. The enzymatic activities of pyruvate carboxylase
in lymphocytes and of the mitochondrial respiratory chain
complexes 1–5 in isolated mitochondria from muscle
were normal. Pyruvate dehydrogenase activity was low
normal (5.8 nmol/(min.mg protein), reference range
5.6–9.4) with mildly reduced E3 lipoamide dehydrogenase
activity (111 nmol/(min.mg protein), reference range
173–288).
Patient 4
This 1 year old-male infant was referred because of a
2-day history of severe metabolic acidosis. He was the
second son of healthy non-consanguineous Italian par-
ents. Pregnancy and delivery were unremarkable, birth
weight was 2.940 kg (50th percentile), and head circum-
ference 34.5 cm (50th percentile) with normal Apgar
scores and normal blood gases. He was diagnosed at
birth with bilateral glaucoma. At age 5 months, the child
presented with poor feeding and mild psychomotor re-
tardation initially attributed to visual impairment and
frequent hospitalizations for eye surgery.
At 12 months of age during a febrile viral infection, he
was admitted in a severe condition exhibiting pallor,
lower limb hypotonia and upper limb dystonia, and
Kussmaul breathing with a severe metabolic acidosis
(venous pH 7.12 and base excess −21.9), a lactate of
4.1 mM (normal < 2 mM) and 3-hydroxybutyrate of
4.5 mM (normal < 0.1), requiring intubation and ventila-
tion, and massive bicarbonate infusion up to 1 mEq/kg/h.
Urine organic acids showed massive ketosis with increased
3-hydroxyisovaleric acid and 2-methyl-2,3-dihydroxybuty-
ric acid. Blood spot acylcarnitine profile showed increased
C4OH, which was confirmed to be mainly (3R)-OH-C4-
carnitine by plasma analysis. Urine metabolite screening
by tandem mass spectrometry showed increased levels of
S-(2-carboxypropyl) cysteine and S-(2-carboxypropyl) cys-
teamine. Within hours of glucose and electrolytes therapy,
there was a dramatic biochemical improvement with reso-
lution of the acidosis within 24 h. After this episode, blood
lactate and ketones, and urine organic acids remained nor-
mal. CSF lactate and neurotransmitter levels were normal.
A work-up for sepsis or intoxication was negative. Enzym-
atic analysis of biotinidase in plasma and HIBCH and
pyruvate carboxylase in fibroblasts revealed no abnormal-
ities and sequence analysis of SLC19A3 did not reveal any
mutations. A muscle biopsy was performed for enzymatic
studies of mitochondrial respiratory chain complexes
and pyruvate dehydrogenase (129 nmol CO2/(min.mg
protein), reference range: 110–130) activities, which were
all normal.
Brain MRI disclosed abnormally high T2 signal in
multiple cerebral areas including the perirolandic region,
the putamina, globus pallidus, medial thalami, andsymmetrical involvement of the cerebral peduncles, con-
sistent with a Leigh-like syndrome (Fig. 3). On admis-
sion to the metabolic division, the patient showed
hypotonia, hyperreflexia, marked irritability with a par-
tial and transient response when contained, dystonia
with head, trunk and pelvis tilted to the left. He had
poor sucking without drooling, and he did not make
visual contact. A trial with thiamine 100 mg/day, biotin
20 mg/day, and carnitine 200 mg/kg/day did not im-
prove his symptoms. Treatment of the severe and pain-
ful dystonia with deforming posture was challenging
with poor response to benzodiazepines. Cerebral MRI
7 days later showed degenerative atrophy of the lesions
in the midbrain nuclei and pallidum. Magnetic re-
sonance spectroscopy demonstrated a mild lactate peak
in the right globus pallidus. The electroencephalogram
showed slow activity. Somatosensory evoked responses
showed an absent response. The visual evoked potentials
(flash and pattern reversal) were abnormal with no re-
sponse, while the brainstem auditory evoked potentials
were within the normal limits for age. Functional tests
of heart, liver and kidney were normal. Due to swallow-
ing difficulties, a gastrostomy was placed. At the present
age of 3 years, the child has remained stable without
episodes of acidosis despite febrile episodes, and never
exhibited hypoglycemia. He shows failure to thrive, psy-
chomotor retardation, and severe extrapyramidal dys-
tonia. He is not receiving a specific therapy.
Methods
For patients 1 and 2, samples were collected from sub-
jects and parents after informed consent under an IRB
approved research protocol (COMIRB #07-0386) at the
University of Colorado. For patient 3, the study was per-
formed with the approval of the ethical committees of
Hadassah Medical Center and the Israeli Ministry of
Health, and parental consent was given for the DNA
studies. For patient 4, samples were collected and bio-
chemical and molecular testing performed with parental
consent.
Genetic studies
Mutations were identified by molecular studies performed
at each of the centers. For patients 1 and 2, the genomic
DNA was sheared, size selected (~400–600 bp), ligated to
sequencing adapters, and PCR amplified following stan-
dard library preparation. The library was subsequently
enriched for exonic sequences using the SureSelect
Human All Exon 51 Mb Kit (Agilent Technologies, Santa
Clara, California, USA). The exome enriched samples were
sequenced to 100 bp paired-end on a HiSeq2000 (Illumina,
San Diego, California, USA). The reads were aligned to
the human genome assembly GRCh37 using GSNAP
(Genomic Short-read Nucleotide Alignment Program,
Fig. 3 Brain MRI of patient 4. Brain MRI of patient 4 showing lesions in the basal ganglia (1) and mesencephalon (2). Bilateral hyperintensities are
present in the globi pallidi and the left caudate at the age of 12 months (1a) and display progressive degenerative evolution to atrophy after
1 month (1b) and 6 months (1c) of the disease course. The substantia nigra shows acute lesions at 12 months of age (2a) and evolving into
atrophy after 6 months (2b)
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(Genome Analysis Toolkit, v2.1-8-g5efb575). Only non-
synonymous coding variants, coding indels and variants
affecting splice sites were retained for further analysis.
Common variants present in dbSNP and 1000 Genomes
data were filtered out. Parental exome sequencing data was
used to analyze variants following various inheritance
models including dominant (de novo mutations) and
recessive (compound heterozygous, homozygous, and
X-linked hemizygous mutations) models. Only mutations
in a single gene, ECHS1, were identified using an auto-
somal recessive inheritance model.
For patient 3, exonic sequences were enriched in the
DNA sample of the patient using SureSelect Human All
Exon 50 Mb Kit (AgilentTechnologies, Santa Clara,
California, USA). Sequences were determined by HiSeq2000
(Illumina, San Diego, California, USA) and 100-bp were
read paired-end. Reads alignment and variant calling
were performed with DNAnexus software (Palo Alto,
California, USA) using the default parameters with the
human genome assembly hg19 (GRCh37) as a reference.
Aligning the patient’s 50.80 million reads to the reference
human genome revealed 141,096 variants. After removal
of variants of low depth (<×8), deep intronic, and those
present in dbSNP132 or in the in-house dbSNP, variants
were sorted for autosomal recessive inheritance mode and
for predicted pathogenicity by Mutation Taster software.
Only a single set of heterozygous mutations was identified,
and these were localized in the ECHS1 gene.
In patient 4, genomic DNA was extracted from cultured
skin fibroblasts using standard methods. The exons andflanking intronic sequences of the ECHS1 gene were se-
quenced after amplification by PCR from genomic DNA
using intronic primers with −21 M13 (5′-TGTAAAAC
GACGGCCAGT-3′) or M13-Rev (5′-CAGGAAACAGC
TATGACC-3′) extensions. PCR fragments were se-
quenced with −21 M13 and M13-Rev sequence primers
using BigDye Terminator cycle sequencing kits (Applied
Biosystems, Foster City, CA, USA). Mutations in pa-
tients 1–3 were verified by Sanger sequencing. Sequence
data were compared to the reference ECHS1 sequence
[GenBank:NM_004092] with nucleotide numbering start-
ing at the first adenine of the translation initiation codon
ATG.
RNA isolation and real-time quantitative PCR (RT-qPCR)
RNA was extracted from the patient 1 skeletal muscle,
as well as from 3 control pediatric muscle specimens.
RNA isolation, cDNA synthesis and RT-qPCR was
performed as described [9]. The following DLAT cDNA
specific primers were used: GGCCAACCGAAGTAACA
GAT (forward) and GCTGAAGGTGTAGGAGCTAAAG
(reverse). All qRT-PCR reactions were performed in tripli-
cate and normalized to GAPDH expression in the tissue.
Enzyme assays and immunoblot analysis
SCEH
SCEH activity was measured in cultured skin fibroblasts
of patients 1–4 and in liver from patients 1 and 2. SCEH
activity with crotonyl-CoA (C4:1-CoA) as substrate was
determined as described in [6]. SCEH activity with
methacrylyl-CoA and tiglyl-CoA was measured after
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recombinantly expressed isobutyryl-CoA dehydrogenase
(IBD) and short-branched-chain acyl-CoA dehydrogenase
(SBCAD), respectively. Purified IBD and SBCAD were a
kind gift from Dr. J. Vockley (University of Pittsburgh,
Pennsylvania) and were prepared as described in [10, 11].
The pre-incubation mixture consisted of 100 mM Tris
pH 8.0, 0.4 mM ferrocenium, 50 μM flavin adenine
dinucleotide, 0.1 mg/ml bovine serum albumin and 0.005
U IBD plus 0.19 mM isobutyryl-CoA, or 0.005 U SBCAD
plus 0.19 mM 2-methylbutyryl-CoA respectively. After
4 min of preincubation at 37 °C all isobutyryl-CoA and
2-methylbutyryl-CoA was converted into methacrylyl-
CoA and tiglyl-CoA, respectively. Incubation was started
by adding fibroblast homogenate (5 μg) or liver homogen-
ate (1.5 μg) and stopped after 5 min at 37 °C. Substrates
and products were separated by ultra-high performance
liquid chromatography allowing calculation of enzyme ac-
tivity. SCEH activity with 3-methylcrotonyl-CoA as sub-
strate was performed in an incubation mixture consisting
of 100 mM Tris pH 7.5, 100 mM potassium chloride,
5 mM adenosine triphosphate, 5 mM magnesium chloride,
120 mM sodium bicarbonate, 2 mM 3-methylcrotonyl-
CoA and 8 μg fibroblast homogenate. Reactions were
allowed to proceed for 15 min at 37 °C. Substrate and
product were separated by high performance liquid chro-
matography allowing calculation of enzyme activity. All
measurements were performed in duplicate.
SCEH protein was analyzed by immunoblot analysis as
described in [6]. As a loading control, the membranes were
reprobed with a monoclonal antibody against α-tubulin
(Molecular probes), using a 1:5000 dilution. Antigen-
antibody complexes were visualized with IRDye 800CW
goat anti-rabbit secondary antibody for SCEH and IRDye
680RD donkey anti-mouse secondary antibody for tubulin
using the Odyssey Infrared Imaging System (LI-COR
Biosciences, Nebraska, USA). Quantification of the signal
intensities of the SCEH and tubulin bands was done using
AIDA Image analyzer software (Version 4.26, Raytest,
Straubenhardt, Germany).
Pyruvate dehydrogenase and α-ketoglutarate
dehydrogenase
In muscle and liver of patients 1 and 2, pyruvate dehydro-
genase, both activated-dephosphorylated and inactivated
phosphorylated, α-ketoglutarate dehydrogenase and E3 ac-
tivities were determined as previously described [12, 13].
In fibroblasts and in HepG2 cells, pyruvate dehydrogenase
activity and α-ketoglutarate dehydrogenase were mea-
sured as described [14–16]. HepG2 cells were incubated
for 1 h on ice in increasing amounts of either methacrylic
acid or acrylic acid (1 nM, 100 nM, 1 μM, or 100 μM)
followed by measurement of pyruvate dehydrogenase ac-
tivity. All samples were assayed in triplicate.The protein components of the pyruvate dehydrogenase
complex were analyzed by immunoblot using a pyruvate
dehydrogenase antibody cocktail which recognizes E2, E3-
binding protein, E1α and E1β (MSP02 Mitosciences,
Eugine, OR), and also with an antibody which recognizes
the E2 and the E3-binding protein (MSP06, Mitosciences,
Eugene, OR) (regardless of lipoylation status).
Glycine cleavage enzyme
The activity of the glycine cleavage enzyme was deter-
mined using a modification of a previously published
method [17, 18] as follows. Approximately 20 mg of liver
tissue from each patient was homogenized in homo-
genization buffer (20 mM Tris–HCl, pH 8.0, 1 mM dithio-
treitol, 1 mM pyridoxal phosphate, 10 μg/ml leupeptin).
Homogenates were then assayed in 0.05 M Tris–HCl,
pH 8.0, 1 mM tetrahydrofolate in β-mercaptoethanol buf-
fer, 0.066 mg/ml nicotinamide adenine dinucleotide, and
2.5 μCi 14C-glycine at 37 °C in a shaking water bath. The
reaction was terminated after 30 min with the addition of
25 % tricholoroacetic acid and incubated for an additional
60 min to ensure that all evolved radioactive CO2 released
was trapped in the potassium hydroxide well. The amount
of 14CO2 was quantified by beta scintillation counting,
and calculated as pmol CO2 evolved/(hr.mg protein).
Fatty acid oxidation studies
Palmitate loading test
Quantitative acylcarnitine profiling by tandem mass
spectrometry was performed in the medium of cultured
skin fibroblasts after loading with [U-13C] palmitic acid
and L-carnitine for 96 h, essentially as described in [19].
Metabolite analysis
Detection of 2-methyl-2,3-dihdroxybutyrate using
gaschromatography-mass spectrometry (GC-MS)
Tissue culture media from fibroblasts of patient 1 and pa-
tient 2 and a normal control were analyzed for the pre-
sence of 2-methyl-2,3-dihydroxybutyrate using GC-MS.
The internal standard dimethylmalonic acid was added to
3 ml of media. Samples were extracted with ether/ethyl
acetate and the external standard C-24 (n-tetracosane) was
added. The samples were dried under a stream of nitrogen.
The residue was then derivatized with bis(trimethylsilyl)-
trifluoroacetamide with 1 % trimethylchlorosilane and in-
cubated for 20 min at 80 °C. The sample was then diluted
in cyclohexane:pyridine:hexamethyldisilazan and subjected
to GC-MS analysis.
Measurement of tissue acyl-CoAs using flow-injection
tandem mass spectrometry
Acyl-CoAs were measured in liver from four control







































Fig. 4 SCEH enzyme activity and protein expression in patients
fibroblasts (a) SCEH enzyme activity with crotonyl-CoA as substrate
measured in fibroblasts of control subjects (n= 10) and fibroblasts of
patients 1–4. Whiskers indicate mean ± SD. Patient fibroblasts show a
markedly reduced SCEH activity. b Immunoblot analysis with antibodies
against SCEH in fibroblasts of two control subjects and fibroblasts of
patients 2–4. The lower panel shows the loading control with
antibodies against α-tubulin. Patient fibroblasts show reduced
SCEH protein expression
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Identification of SCEH deficiency in four novel patients
In patients 1–3, mutations were identified in the ECHS1
gene by exome sequencing with diagnosis confirmed by
enzymatic analysis of SCEH activity in skin fibroblasts.
In patient 4, SCEH deficiency was suspected based on
metabolite abnormalities and confirmed by enzymatic
analysis in cultured fibroblasts and molecular analysis of
the ECHS1 gene by Sanger sequencing.
Genetic studies
Whole exome sequencing identified three different muta-
tions in the ECHS1 gene of patients 1–3. Patients 1 and 2
were homozygous for c.817A >G (p. K273E). Patient 3
was compound heterozygous for c.433C > T (p.L145F) and
c.476A >G (p.Q159R). For patient 4 direct sequencing of
the ECHS1 gene revealed the following heterozygous mu-
tations: c.673 T > C (p.C225R) and c.674G > C (p.C225S).
The identified mutations were extremely rare in the
general population, presenting only in a heterozygous state
in 3 (c.817A >G), 0 (c.433 C > T), 14 (c.476A >G),
1 (c.673 T > C) and 1 (c.674G > C) of 61,486 unrelated in-
dividuals (Exome Aggregation Consortium (ExAC), Cam-
bridge, MA (URL: http://exac.broadinstitute.org), accessed
Dec. 2014). Carrier status of the different mutations was
confirmed by Sanger sequencing in the respective parents.
Biochemical studies
SCEH activity with crotonyl-CoA and SCEH protein
expression in fibroblasts
SCEH activity measured with crotonyl-CoA as substrate
was markedly reduced in cultured skin fibroblasts from all
patients compared to the SCEH activity in control fibro-
blasts (mean ± SD in control fibroblasts: 379 ± 145 nmol/
(min.mg)). The SCEH activity in patient 1 and 2 was below
the limit of detection of our enzymatic assay (<9 nmol/
(min.mg)), whereas the activity was 12 nmol/(min.mg) in
patient 3 and 20 nmol/(min.mg) in patient 4 (Fig. 4a).
Immunoblot analysis of fibroblast homogenates from the
patients revealed the absence of the 27-kDa band corre-
sponding to SCEH in patient 2 and 3, whereas a small
amount of residual SCEH protein could be detected in the
homogenate from patient 4 (Fig. 4b).
Palmitate loading test
To study the role of SCEH in mitochondrial fatty acid
oxidation, a palmitate loading test was performed in
fibroblasts of patient 1–4, which did not reveal any ab-
normalities (see Table 1). The levels of acylcarnitines ex-
creted in the medium after loading the fibroblasts with
[U-13C] Palmitate for 96 h were normal, including the
level of labeled C2-, C4-, C4:1-carnitine and unlabeled
C5:1-carnitine.Activity measurements with methacrylyl-CoA, tiglyl-CoA and
3-methylcrotonyl-CoA in fibroblasts
To investigate substrate specificity of SCEH, activity
measurements were performed with different substrates
in cultured fibroblasts of the SCEH-deficient patients
and fibroblasts of two patients with a deficiency of other
mitochondrial enoyl-CoA hydratases: one patient with
mitochondrial trifunctional protein (MTP) deficiency
and one patient with 3-methylglutaconyl-CoA hydratase
(MGH) deficiency. Methacrylyl-CoA and tiglyl-CoA
were formed in a preincubation with recombinantly
expressed IBD and SBCAD from isobutyryl-CoA and
2-methylbutyryl-CoA, respectively. After 4 min, all
isobutyryl-CoA and 2-methylbutyryl-CoA was converted
into methacrylyl-CoA and tiglyl-CoA (Fig. 5a). Fibroblasts
from patient 2 and 3 revealed a virtually complete defi-
ciency of enoyl-CoA hydratase activity with methacrylyl-
CoA and tiglyl-CoA as substrates, whereas fibroblasts
Table 1 Palmitate loading test with [U-13C] Palmitate in fibroblasts of SCEH deficient patients
Acyl-carnitines Patient 1 Patient 2 Patient 3 Patient 4 Reference range
nmol/(96 hr.mg) nmol/(96 hr.mg) nmol/(96 hr.mg) nmol/(96 hr.mg) nmol/(96 hr.mg)
[U-13C] C2 16.75 11.01 21.49 19.88 2.3–43.3
C3 0.42 0.10 0.11 0 0–2.3
[U-13C] C4 1.06 0.31 0.43 0.93 0–2.0
C5 0.57 0.20 0.00 0 0–2.5
[U-13C] C6 0.31 0.15 0.26 0.78 0–1.4
[U-13C] C8 0.31 0.20 0.47 0.82 0.1–2.6
[U-13C] C10 0.31 0.26 0.79 0.73 0.2–3.1
[U-13C] C12 0.09 0.04 0.14 0.08 0–0.8
[U-13C] C14 0.05 0.09 0.05 0.04 0–0.4
[U-13C] C16 1.58 0.64 1.04 2.75 0–4.3
C16/C2 ratio 0.10 0.06 0.05 0.14 0–0.32
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activity measured in control fibroblasts) (Fig. 5b). In con-
trast, the MTP- and MGH-deficient fibroblasts revealed
normal enoyl-CoA hydratase activity, similar to the control
fibroblasts (see Fig. 5b). Next, enoyl-CoA hydratase activity
with 3-methylcrotonyl-CoA as substrate was measured by
determining the formation of 3-hydroxyisovaleryl-CoA.
Also for 3-methylcrotonyl-CoA as substrate, fibroblasts of
patient 2 and 3 revealed a near complete deficiency of
enoyl-CoA hydratase activity, with residual activity (20 %)
in fibroblasts of patient 4 and normal activity in fibroblasts
of the MTP- and MGH-deficient patient.
SCEH activity measurements in liver
SCEH activity with crotonyl-CoA, methacrylyl-CoA and
tiglyl-CoA was measured in liver from patients 1 and 2
and two control subjects. The enoyl-CoA hydratase ac-
tivities in patients 1 and 2 were 4 and 5 % with crotonyl-
CoA, 7 and 5 % with methacrylyl-CoA and 24 and 22 %
with tiglyl-CoA, respectively, of the mean activity in two
control liver samples (Fig. 5c). The specific activity with
crotonyl-CoA in the control livers samples was 14–15
fold higher than with methacrylyl-CoA and tiglyl-CoA,
which means that the residual activity with crotonyl-
CoA in the SCEH deficient livers was similar to the ac-
tivity with methyacrylyl-CoA and tiglyl-CoA in control
livers.
Liver acyl-CoA measurements
Tissue acyl-CoAs were determined in liver from four
control subjects and patient 2 by flow-injection tandem
mass spectrometry. Medium- and short-chain acyl-CoAs
(C4, C8, C8:1, C10:1) were mildly increased, and
hydroxy-C6-CoA was mildly decreased, but no dif-
ference was found in the level of C4:1-CoA (reflecting
both crotonyl-CoA and methacrylyl-CoA). Tiglyl-CoA
tended to be at the low limit (Additional file 1).Bioenergetics analysis
To resolve the source of the severe lactic acidosis in pa-
tients 1 and 2, enzyme activities of the respiratory chain
and of pyruvate dehydrogenase were measured. The re-
spiratory chain enzyme activities and the assembly of the
complexes on blue native gel analysis were normal in all
tissues in both patients (Additional file 2). In contrast,
the activity of the pyruvate dehydrogenase enzyme was
markedly decreased in muscle and liver, and was border-
line low in fibroblasts (Table 2). Given the presence of
sulfur adducts derived from methacrylyl-CoA with cyst-
eine and cysteamine, we hypothesized that methacrylyl-
CoA could generate adducts to lipoic acid, another free
sulfur containing intramitochondrial compound. We
therefore measured the activities of other lipoic acid car-
rying enzymes, α-ketoglutarate dehydrogenase and the
glycine cleavage enzyme, in patients 1 and 2, but found
the activities to be normal or even increased (Table 2).
We next investigated whether the accumulating free
acids acrylic acid or methacrylic acid could be respon-
sible for decreased activity of the pyruvate dehydro-
genase enzyme. We incubated HepG2 cells, a model of
human liver cells, with increasing concentrations of
acrylic acid and methacrylic acid and measured pyruvate
dehydrogenase enzyme activity. This activity was not af-
fected by the presence of these metabolites at any con-
centration that would conceivably be present in patient
tissues (Additional file 3).
We next evaluated if the deficient activity of pyruvate
dehydrogenase was due to a functional deficiency or was
due to a specific protein defect by performing Western
blot analysis of various protein components of the pyru-
vate dehydrogenase complex. A specific decrease in the
E2 protein component of pryruvate dehydrogenase was
noted using various antibodies, whereas other com-
ponents of the pyruvate dehydrogenase complex were
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Fig. 5 SCEH enzyme activity in patient fibroblasts measured with different substrates. a Formation of tiglyl-CoA by incubation of 2-methyl-butyryl-CoA
with recombinantly expressed short branched-chain acyl-CoA dehydrogenase (SBCAD) (left panel) and formation of methacrylyl-CoA by incubation of
isobutyryl-CoA with isobutyryl-CoA dehydrogenase (IBD) (right panel). After 2 min all substrate is converted into product. b Enoyl-CoA hydratase enzyme
activity with tiglyl-CoA (left graph), methacrylyl-CoA (middle graph) and 3-methylcrotonyl-CoA (right graph) in fibroblasts of two control subjects, SCEH
deficient patients and a patient with a complete deficiency of mitochondrial trifunctional protein (MTP) and a patient with 3-methylglutaconyl-CoA
hydratase (MGH) deficiency. c Enoyl-CoA hydratase enzyme activity with tiglyl-CoA (left graph), methacrylyl-CoA (middle graph) and crotonyl-CoA
(right graph) in liver of two control subjects and two SCEH deficient patients (patient 1 and 2). Residual activity in patients samples is indicated in % of
mean activity in two control liver samples
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fected tissues, but less in cultured fibroblasts where the
enzyme activity was borderline. We did not identify mu-
tations in the coding sequence of the DLAT gene that
could explain this decrease. Subsequently, we performed
RT-qPCR for E2 subunit mRNA to determine if thedeficiency in E2 and pyruvate dehydrogenase activity
was due to decreased expression of the DLAT gene, ver-
sus a defect in translation or increased protein degra-
dation. Expression of E2 mRNA was higher in patient 1
(normalized relative expression of four) compared with
mRNA from three control skeletal muscle specimens
Table 2 Analysis of bioenergetics enzymes in patients 1 and 2
Patient 1 activitya (% mean) Patient 2 activity (% mean) Mean ± SD Range
Fibroblasts:
PDHC, Activatedb 0.88 (53 %) 0.83 (50 %) 1.66 ± 0.67 0.87–3.03
PDHC, Activatedc NA 1.11 (46 %) 2.42 ± 0.88 1.26–4.42
PDHC, Inactivated NA 0.48 (52 %) 0.92 ± 0.63 0.19–2.30
E3 NA 30.5 (51 %) 60 ± 20 24.5–98.4
PDHC/E3 Ratio NA 3.64 (99 %) 3.69 ± 1.16 2.15–6.57
2-ketoglutarate dehydrogenase 0.84 (80 %) 0.81 (77 %) 1.05 ± 0.28 0.68–1.58
Liver:
PDHC, Activatedc 0.88 (41 %) 0.33 (15 %) 2.17 ± 0.77 1.23–3.89
PDHC, Inactivated 0.22 (37 %) 0.03 (5 %) 0.6 ± 0.43 0.07–1.80
E3 129 (75 %) 178.8 (105 %) 171 ± 46 102.0–266.0
PDHC/E3 Ratio 0.68 (56 %) 0.18 (15 %) 1.22 ± 0.54 0.67–2.36
2-ketoglutarate dehydrogenase 5.64 (265 %) NA 2.16 ± 0.99 0.68–3.48
Glycine Cleavage Enzyme 74.9 (96 %) 134.0 (171 %) 78.2 ± 40.1 29.6–163.1
Muscle:
PDHC, Activatedc 0.29 (9 %) 0.10 (3 %) 3.17 ± 1.49 1.20–6.52
PDHC, Inactivated 0.15 (31 %) 0.07 (15 %) 0.48 ± 0.5 0.06–1.39
E3 20 (16 %) 25 (20 %) 128 ± 39 72.0–222.0
PDHC/E3 Ratio 1.45 (64 %) 0.40 (18 %) 2.27 ± 1.02 0.82–4.54
The activity of the pyruvate dehydrogenase and 2-ketoglutarate dehydrogenase enzyme components is given in nmol/(min.mg protein) as well as in % of normal
activity. aActivity in nmol/(min.mg protein); Activated PDHC complex activities were measured in Coloradob and in Ohioc. NA Not available
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indicating that lower pyruvate dehydrogenase activity is
not caused by a transcriptional decrease.
Discussion
In this paper we describe four patients with SCEH defi-
ciency, which was recently identified as a novel disorder.
All patients presented with a substantial metabolic acid-
osis with lactic acidosis. Ketosis was present but variable,
in some patients mild, in others more pronounced. The
first two patients presented with vacuolating leukoence-
phalopathy and basal ganglia abnormalities. This clinical
picture is typically seen in female patients with severe
pyruvate dehydrogenase deficiency. The fourth patient
showed Leigh-like lesions with a single metabolic acid-
osis episode, similar to what has been described in the
previously published patients and what can be seen in
patients with bioenergetic disturbances including pyru-
vate dehydrogenase deficiency. The third patient rather
showed a slow neurodegenerative condition with global
brain atrophy. All patients were either homozygous or
compound heterozygous for mutations in the ECHS1
gene. Results of the enzyme activity measurements and
immunoblot analysis strongly suggest that there is a cor-
relation between the residual SCEH enzyme activity and
the severity of the clinical symptoms (from below the
detection limit in patients with neonatal presentation tosubstantial residual activity in the patient with late infantile
presentation).
SCEH is believed to be one of the enzymes responsible
for the β-oxidation of medium- and short-chain fatty
acyl-CoAs in the mitochondria [2]. The patients pre-
sented with metabolic acidosis but showed a variable de-
gree of ketosis and no hypoglycemia. Crotonyl-glycine
and crotonyl-carnitine were not detected in plasma and
urine. To investigate this apparent discrepancy between
the observations in the patients and the postulated crucial
role of SCEH in mitochondrial fatty acid β-oxidation, we
performed a palmitate loading test in fibroblasts of the pa-
tients. Just like in plasma and urine of the patients, no
butyrylcarnitine or crotonylcarnitine could be detected in
the medium of the cells loaded with palmitate. It is known
that crotonyl-CoA is a poor substrate for the human car-
nitine acetyltransferase [21], but the absence of butyrylcar-
nitine was unexpected since butyrylcarnitine can readily
be detected after loading fibroblasts of patients with short-
chain acyl-CoA dehydrogenase (SCAD) (MIM201470)
[22] or short-chain 3-hydroxyacyl-CoA dehydrogenase
(SCHAD) (MIM231530) [23] deficiency. Moreover, pa-
tients became ketotic which points to a substantial rate of
in vivo fatty acid oxidation, albeit probably somewhat less
than expected for the clinical situation. Taken together, it
can be concluded from these results that in fibroblasts









































Fig. 6 Pyruvate dehydrogenase subunits in tissue samples. Levels of subunits of pyruvate dehydrogenase are shown in liver (a), muscle (b) and
fibroblasts (c). Five control samples are shown followed by samples of patients 1 and 2. Decreased levels of the E2 subunit are shown when
probed with a pyruvate dehydrogenase antibody cocktail, as well as with an antibody specific to E2 and E3-binding protein. GAPDH, porin and
citrate synthase are shown as loading controls
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chondrial β-oxidation system since both expression of
SCEH and its activity towards straight-chain fatty acyl-
CoAs is high, or that another enzyme is additionally in-
volved in fatty acid oxidation and can at least partially take
over in case of an SCEH deficiency. Fibroblasts of patients
with a deficiency of MTP and MGH, which both harbor
mitochondrial enoyl-CoA hydratase activity, display nor-
mal hydratase activity with crotonyl-CoA as substrates,
excluding these enzymes as responsible for the residual
crotonase activity. Candidates could be ECHDC2 and
ECHDC3 which are genes predicted to have proteinproducts with mitochondrial enoyl-CoA hydratase activity
and with similar expression profiles as ECHS1, and should
be further researched.
Interestingly, purified crotonase (SCEH) has also been
shown to act towards tiglyl-CoA as substrate suggesting
a role for SCEH in isoleucine metabolism [4] (Fig. 7).
However, no tiglyl-glycine was detected in urine of the
patients. Increased excretion of tiglyl-glycine is a feature
of 2-methyl-3-hydroxybutyryl-CoA dehydrogenase defi-
ciency (MIM 300438) and mitochondrial acetoacetyl-
CoA thiolase deficiency (MIM 203750). These inborn













Fig. 7 Tiglyl-CoA metabolism. The intersecting enzyme activities acting upon tiglyl-CoA in liver tissue
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Hydratase activity measurements with tiglyl-CoA as sub-
strate in SCEH deficient fibroblasts demonstrated that
SCEH is indeed involved in isoleucine metabolism, at least
in fibroblasts. Measurement of hydratase activity with
3-methylcrotonyl-CoA as substrate revealed that SCEH is
responsible for production of 3-hydroxyisovaleryl-CoA. In
contrast to metabolites of the fatty acid oxidation pathway
and the isoleucine catabolic pathway, metabolites of the
valine catabolic pathway are readily detected in plasma
and urine of SCEH deficient patients and are also believed
to play an important role in the underlying pathology of
the disorder. In conclusion, the results of the enzyme ac-
tivity measurements in fibroblasts with a complete SCEH
deficiency with the different substrates together with the
metabolite abnormalities in SCEH deficient patients imply
that there must be another hydratase that is also active to-
wards crotonyl-CoA and tiglyl-CoA but not methacrylyl-
CoA in other organs, or the residual SCEH activity with
crotonyl-CoA and tiglyl-CoA, but not methacrylyl-CoA, is
sufficient to maintain flux through the respective catabolic
pathways. Subsequent enzyme activity measurements with
the different substrates in liver from the most severely af-
fected patients showed that in case of SCEH deficiency
there is considerable residual hydratase activity with tiglyl-
CoA. Thus, there must be another enzyme which is
responsible for this activity, preventing accumulation of
tiglyl-CoA and its derived metabolites such as tiglylglycine
(Fig. 7). This activity is not present for methacrylyl-CoA
resulting in the presence of increased metabolites, whereas
for crotonyl-CoA the residual hydratase activity was low
but apparently sufficient to allow ketosis to occur. Thus,SCEH is a crucial enzyme in valine metabolism but not
isoleucine metabolism, and appears to be only of limited
importance for mitochondrial fatty acid oxidation. This
conclusion is supported by the mildly increased levels of
short and medium straight-chain acyl-CoAs in liver of one
of the SCEH deficient patients, whereas by comparison,
C4-CoA levels are 7-fold increased in livers from SCAD
knock out mice [20].
The pathophysiology of this condition is unclear. The
persistent lactic acidosis suggested a disturbance of bio-
energetics, which is also compatible with the clinical
presentations of Leigh-like lesions in basal ganglia and
brain stem nuclei, and with a periventricular necrotizing
leukoencephalopathy. Therefore, the question arose at
what level energy generation was disturbed. Extensive
enzymatic analysis demonstrated deficient activity of
pyruvate dehydrogenase in muscle to a very low level,
and to a lesser extent in liver and fibroblasts of patients
1 and 2, the most severely affected patients. Given that
the accumulating methacrylyl-CoA reacts with exposed
thiol groups and makes adducts with cysteine and cyste-
amine [25], methacrylyl-CoA could react with the lipoyl
domain of pyruvate dehydrogenase complex, thereby
reducing its activity [8]. For that reason, we studied
whether the activities of two other enzymes containing a
lipoyl domain, 2-ketoglutarate dehydrogenase and the
glycine cleavage enzyme, were affected, but the activity
of both enzymes was normal, thus illustrating the speci-
ficity of the deficiency in pyruvate dehydrogenase. Next,
we considered that accumulating methacrylate or acryl-
ate could directly intoxicate and impair the pyruvate
dehydrogenase enzyme, but we did not observe an
Ferdinandusse et al. Orphanet Journal of Rare Diseases  (2015) 10:79 Page 14 of 15inhibitory effect after incubating HepG2 cells with in-
creasing concentrations of these compounds. It should
be noted that it is not sure that the methacrylate or
acrylate added to the medium reaches the mitochondria
without being metabolized. Methacrylyl-CoA, which
could not be tested because it is not stable, is more re-
active with cysteine residues than free methacrylic acid
[25]. Hence the absence of an inhibition with the free
acid in this experimental set-up does not exclude a dir-
ect inhibitory effect of the free acid or the CoA-ester by
for instance reacting with the active center cysteine 62
of the E1α subunit of pyruvate dehydrogenase. However,
in contrast to this hypothesis, Western blot analysis of
pyruvate dehydrogenase enzyme showed markedly re-
duced levels of the E2 protein in the most affected tis-
sues muscle and liver, but not in fibroblasts. Analysis of
mRNA levels of the E2 subunit of pyruvate dehydroge-
nase revealed an increased level of E2 message in skel-
etal muscle, suggesting that the decrease in activity is
related to an effect on E2 protein translation or stability.
This should be studied further when tissues of additional
patients become available.
This effect on pyruvate dehydrogenase was only
present in the most severely affected patients 1 and 2.
The pyruvate dehydrogenase activity was borderline nor-
mal in the less severely affected patient 3 and normal in
patient 4 when tested outside an acute crisis. In fibro-
blasts from previously published patients with an equally
severe deficiency similarly low pyruvate dehydrogenase
enzyme activity was noted [6]. Surprisingly, low activities
of respiratory chain enzymes I, III, and IV were noted in
a muscle biopsy of another patient [7], which is different
from the findings in our four patients as well as both
previously published patients [6], but pyruvate dehydro-
genase enzyme activity was not reported.
Secondary deficiencies of enzymes involved in bioener-
getics were also reported in patients with HIBCH defi-
ciency. HIBCH is the next enzyme in the valine catabolic
pathway [5] and HIBCH deficient patients excrete the
same metabolites in urine (i.e. S-(2-carboxypropyl)cysteine,
S-(2-carboxypropyl)cysteamine, S-(2-carboxyethyl)cysteine,
S-(2-carboxypropyl)cysteamine and 2-methyl-2,3-dihy-
droxybutyrate) as SCEH deficient patients [25, 6]. Most
commonly, patients with HIBCH deficiency have a com-
bined respiratory chain deficiency resulting in Leigh-like
syndrome [8, 26, 27] with a reduced protein level of com-
plexes I and IV [8, 26]. Additionally, pyruvate dehydrogen-
ase activity was reduced in two patients [8, 27], but not in
others [8, 26]. Thus, with disorders in the valine pathway
a complex interrelationship exists of accumulating me-
tabolites and decreased activities in the bioenergetics
pathway, the mechanism of which is not completely eluci-
dated but seems to involve decreased protein levels, which
could be through either decreased synthesis or enhanceddegradation. In our study, the degree of SCEH deficiency
seems to correlate with the degree of the secondary defi-
ciency of these bioenergetic enzymes and with the severity
of the clinical symptoms. Diagnostically, reduced enzyme
activity of pyruvate dehydrogenase particularly with re-
duced amounts of the E2 component should alert to the
possibility of SCEH deficiency, in addition to the presence
of the marker metabolite 2-methyl-2,3-hydroxybutyric
acid in urine organic acids [6]. The exact origin of 2-
methyl-2,3-dihydroxybutyrate is currently unknown. Des-
pite complete deficiencies of the enzymatic activities in
fibroblasts, the compound could not be detected in the
supernatant of cultured patient’s fibroblasts (not shown),
indicating that it is not likely synthesized in this cell type.
Conclusion
Our studies show that there is a correlation between the
residual enzyme activity and the severity of the clinical
presentation in SCEH deficiency. Despite its broad sub-
strate specificity, SCEH appears only to be crucial in valine
catabolism and not in isoleucine catabolism, and only of
limited importance for mitochondrial fatty acid oxidation.
SCEH deficiency can cause a secondary deficiency in
mitochondrial bioenergetics resulting in metabolic acid-
osis and Leigh-like syndrome.
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in mitochondrial extracts of HepG2 cells after incubation with
methacrylic and acrylic acid.
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